Top-accessed article: Defining urticarial dermatitis.

chance, not choice. Lancet. 2002;359(9305):515-519. 61. Day SJ, Altman DG. Statistics notes: blinding in clinical trials and other studies. BMJ. 2000;321(7259):504. 62. Taı̈eb A, Picardo M; VETF Members. The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res. 2007; 20(1):27-35. 63. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210-216. 64. Lewis-Jones MS, Finlay AY. The Children’s Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol. 1995;132(6):942-949. 65. Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol. 1997;133(11):1433-1440. 66. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials. J Pharmacol Pharmacother. 2010;1(2):100-107. 67. Parsad D, Pandhi R, Dogra S, Kumar B. Clinical study of repigmentation patterns with different treatment modalities and their correlation with speed and stability of repigmentation in 352 vitiliginous patches. J Am Acad Dermatol. 2004; 50(1):63-67. 68. Picardo M, Taı̈eb A. Evaluation, assessment, and scoring. In: Picardo M, Taı̈eb A, eds. Vitiligo. New York, NY: Springer. 2011:127-134. 69. Njoo MD, Das PK, Bos JD, Westerhof W. Association of the Köbner phenomenon with disease activity and therapeutic responsiveness in vitiligo vulgaris. Arch Dermatol. 1999;135(4):407-413. 70. Simon R. Confidence intervals for reporting results of clinical trials. Ann Intern Med. 1986;105(3):429-435. 71. Shih WJ. Problems in dealing with missing data and informative censoring in clinical trials. Curr Control Trials Cardiovasc Med. 2002;3(1):4. 72. Higgins JP, Altman DG. Assessing risk of bias in included studies. http://onlinelibrary .wiley.com/doi/10.1002/9780470712184.ch8/summary. Accessed July 6, 2011. 73. Eleftheriadou V, Whitton ME, Gawkrodger DJ, et al; vitiligo priority setting partnership. Future research into the treatment of vitiligo: where should our priorities lie? Results of the vitiligo priority setting partnership. Br J Dermatol. 2011; 164(3):530-536. 74. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991;337(8746):867-872. 75. Bigby M, Williams H. Appraising systematic reviews and meta-analyses. Arch Dermatol. 2003;139(6):795-798. 76. Ioannidis JPA. Contradicted and initially stronger effects in highly cited clinical research. JAMA. 2005;294(2):218-228. 77. Chalmers I. Underreporting research is scientific misconduct. JAMA. 1990;263 (10):1405-1408.